IMMUNEXPRESS
Immunexpress Pty Ltd, a molecular diagnostics company, develops clinical assays for the management of immune disorders. It focuses on the early detection and management of sepsis patients; and the early identification of sepsis in patients at risk. The company engages in the discovery and clinical validation of genomic and proteomic biomarkers; and the translation of these biomarkers into clinical diagnostic and monitoring assays for readily available platforms, including point-of-care. It devel... ops SeptiCyte gene expression products, including SeptiCyte Triage for use in emergency and intensive care units (ICUs) or upon hospital admission as a screening tool to diagnose sepsis from other forms of systemic inflammation in adult patients; SeptiCyte STAT for use in ICUs and post-operative wards to monitor and detect sepsis at the earliest possible time in patients who are at high-risk of developing sepsis; and SeptiCyte RTT, a tool for monitoring ICU patients with sepsis to determine the patient’s immune status and the response of their immune system to therapy. The company was formerly known as Athlomics Pty Ltd and changed its name to Immunexpress Pty Ltd in 2011. Immunexpress Pty Ltd was founded in 2006 and is based in Brisbane, Australia with an additional office in Seattle, Washington.
IMMUNEXPRESS
Industry:
Biotechnology Genetics Health Diagnostics Pharmaceutical
Founded:
2006-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.immunexpress.com
Total Employee:
11+
Status:
Active
Contact:
(206)858-6436
Email Addresses:
[email protected]
Total Funding:
67.02 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Global Site Tag Sitelinks Search Box Euro
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Current Advisors List
Current Employees Featured
Founder
Investors List
Debiopharm Group
Debiopharm Group investment in Debt Financing - Immunexpress
Debiopharm Group
Debiopharm Group investment in Series B - Immunexpress
Debiopharm Group
Debiopharm Group investment in Funding Round - Immunexpress
Debiopharm Group
Debiopharm Group investment in Venture Round - Immunexpress
Biocartis
Biocartis investment in Venture Round - Immunexpress
Official Site Inspections
http://www.immunexpress.com Semrush global rank: 5.8 M Semrush visits lastest month: 1.44 K
- Host name: 193.125.215.35.bc.googleusercontent.com
- IP address: 35.215.125.193
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Immunexpress"
There are daily pills to prevent HIV — but injectable options could ...
22 hours ago Quebec is the first province to publicly cover costs of long-acting injectable HIV prevention medication Apretude. Experts say it's a much-needed, long-awaited tool — and …See details»
Immunexpress Home - Immunexpress
Immunexpress is a privately-owned group of companies developing and commercializing revolutionary molecular diagnostics to aid clinicians in managing patients with, or suspected …See details»
Immunexpress - Crunchbase Company Profile & Funding
Organization. Immunexpress . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Immunexpress …See details»
About Us - Immunexpress
2 days ago Immunexpress is a privately-owned group of companies developing and commercializing revolutionary molecular diagnostics to aid clinicians in managing patients …See details»
Immunexpress, Inc. - Devex
Immunexpress was founded in Australia in 2006 with the exclusive purpose of developing and commercializing SeptiCyte™ technology. Immunexpress is a privately-owned company with …See details»
Sepsis Alliance Institute: Immunexpress
Immunexpress is a molecular diagnostic company, based in Brisbane and Seattle, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology …See details»
Newsroom - Immunexpress
Jan 4, 2024 Immunexpress Announces U.S. FDA Clearance of EDTA Blood Compatible Cartridges for SeptiCyte RAPID® January 4, 2024 Press Release. Rollie Carlson on How Cross-Training and Extreme Ownership Help You …See details»
About Sepsis - Immunexpress
Immunexpress has partnered with Sepsis Alliance - a non-profit organization dedicated to informing the public about the dangers and risk factors of sepsis and to promoting clinical best-practices for early detection, diagnosis and …See details»
Immunexpress - Company Profile - Tracxn
Mar 1, 2025 Immunexpress develops molecular diagnostics for the detection of sepsis. Its platform technology SeptiCyte uses a proprietary panel of blood-based biomarkers and …See details»
Immunexpress - Technology Networks
Immunexpress is creating revolutionary molecular diagnostics for sepsis. Their goal is to transform sepsis diagnostics by providing clinicians with the technology to enable them to …See details»
Immunexpress Unveils Promising Research at SCCM 2025 on …
Immunexpress aims to combat this issue through its innovative product, SeptiCyte RAPID. This state-of-the-art test utilizes reverse transcription polymerase chain reaction (RT-PCR) to …See details»
Validation - Immunexpress
Jul 30, 2019 Immunexpress is a privately-owned group of companies developing and commercializing revolutionary molecular diagnostics to aid clinicians in managing patients …See details»
Immunexpress to Present New Data at the Society of Critical Care ...
Feb 24, 2025 SEATTLE and BRISBANE, Australia, Feb. 24, 2025 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for …See details»
Immunexpress Company Profile - Craft
Immunexpress is a company creating molecular diagnostics for sepsis. Its SeptiCyte technology quantifies the specific molecular biomarkers, which capture signals from a patient's immune …See details»
Immunexpress Begins US Commercialization of Near-Patient …
Feb 1, 2023 Immunexpress is also building further momentum off data from a recent paper published in Nature Scientific Reports that evaluated the test for use with COVID-19 patients. …See details»
Immunexpress Presents on the Need for an Objective Diagnostic …
Mar 15, 2016 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced the...See details»
FDA clears Immunexpress’ RNA-based, whole-blood sepsis Dx
Feb 22, 2017 Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood, returns results in a few …See details»
Debiopharm invests $6M into Immunexpress for sepsis test …
Mar 6, 2014 Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test. …See details»
Immunexpress to Present SeptiCyte® RAPID Data at the …
Nov 12, 2020 Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that it will present data in two …See details»
Publication in the Journal, Infection, Demonstrates Clinical Utility …
Dec 3, 2024 Immunexpress' SeptiCyte® technology can assess a patient's dysregulated immune response by quantifying and analyzing gene expression from whole blood, providing …See details»